Orchid Pharma Key Ratios

NSE: ORCHPHARMA | BSE: 524372

₹956.10

up-down-arrow-19.50 (-2.00%)

As on 31-Aug-2026 15:09IST

Market cap

info icon

₹5,765 Cr

Revenue (TTM)

info icon

₹943 Cr

P/E Ratio

info icon

665.3

P/B Ratio

info icon

4.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 28.01 15.57 0.20 9.50 17.37
EBIT -83.04 118.87 -92.44 -60.60 15.40
Net Profit -86.10 156.67 -76.03 -28.48 16.58
EPS -88.52 156.64 -87.52 -54.30 15.47
Book Value -- -- 8.36 16.36 5.89
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info 7.380.680.348.259.46
Net Margin info 9.75-0.251.0210.0111.18
Return on equity info 8.790.841.217.8610.23
Return on Capital info 8.844.13--8.059.35
Return on Assets info 5.831.110.555.916.84
Debt to Equity (x) info ----0.250.140.12
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
8.05
9.35
9.11
-2.32
Peer Median
--
16.46
15.49
17.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

1.21

Lower than Peers by 8.73

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
1.21
7.86
10.23
8.27
-8.75
Peer Median
9.94
13.87
14.72
15.70
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

0.55

Lower than Peers by 6.71

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
0.55
5.91
6.84
4.73
-4.85
Peer Median
7.26
8.04
7.19
9.43
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

0.34

Lower than Peers by 9.21

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
0.34
8.25
9.46
4.43
-5.80
Peer Median
9.55
10.05
10.28
13.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

1.02

Lower than Peers by 7.62

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
1.02
10.01
11.18
8.06
-10.01
Peer Median
8.64
9.11
6.78
10.91
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
14.13
15.66
16.52
5.38
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

0.20

Lower than Peers by 6.04

Year on year growth in net sales

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
0.20
12.52
23.05
19.00
24.33
Peer Median
6.24
7.17
10.56
12.63
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-92.44

Lower than Peers by 92.38

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
-92.44
-1.93
162.82
190.95
44.30
Peer Median
-0.06
12.05
6.17
-2.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-76.03

Lower than Peers by 83.61

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
-76.03
0.73
72.07
197.10
40.26
Peer Median
7.58
22.15
27.97
-14.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-87.52

Lower than Peers by 89.70

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
-87.52
8.13
60.13
2,474.06
98.33
Peer Median
2.18
8.80
--
-3.68
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
8.36
69.82
6.37
-0.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.25

Higher than Peers by 0.23

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
0.25
0.14
0.12
0.48
0.41
Peer Median
0.02
0.03
0.05
0.14
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
0.03
0.01
0.20
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.45

Higher than Peers by 0.00

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
2.45
2.83
3.04
1.35
1.60
Peer Median
2.45
2.20
1.93
1.82
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.53

Lower than Peers by 0.18

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
1.53
1.68
2.03
0.73
0.88
Peer Median
1.72
1.72
1.59
1.30
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

1.81

Lower than Peers by 7.90

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
1.81
7.40
6.49
2.68
-0.70
Peer Median
9.71
12.28
12.45
16.98
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

27.99

Higher than Peers by 1.08

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
27.99
26.23
23.87
32.32
30.48
Peer Median
26.91
26.23
23.97
24.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.52

Lower than Peers by 0.15

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
0.52
0.57
0.59
0.57
0.48
Peer Median
0.67
0.74
0.88
0.82
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
86.58
91.49
105.72
99.89
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
116.91
109.80
110.01
106.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
151.46
152.17
162.30
161.59
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
52.03
49.12
53.43
44.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

665.30

Higher than Peers by 610.23

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
665.30
39.54
57.52
33.87
--
Peer Median
55.07
39.17
40.74
25.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.44

Lower than Peers by 0.05

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
4.44
3.11
4.53
2.28
1.79
Peer Median
4.48
3.61
3.87
2.79
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
--
--
--
--
--
Peer Median
0.15
0.19
0.20
0.65
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

90.81

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
90.81
27.13
36.42
18.03
22.34
Peer Median
--
28.79
25.41
15.07
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

5,765

Lower than Peers by 54

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Orchid Pharma
5,765
3,940
5,301
1,569
1,160
Peer Median
5,820
3,944
2,959
3,742
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...